

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis


Bruce A. C. Cree,¹ Jeffrey A. Cohen,² Anthony T. Reder,³ Davorka Tomic,⁴ Diego Silva,⁴ Annik K. Laflamme,⁴ Daniela Piani Meier,⁴ Shannon Ritter,⁵ David Leppert,⁴ and Ludwig Kappos⁶

Appendix

Table of Contents

Figure 1S. Study designs for the TRANSFORS and FREEDOMS/FREEDOMS II trials and their extensions.	2
Figure 2S. EDSS category trends at months 12, 24, 48, and 96 by treatment group in TRANSFORMS (a) the full analysis set (FAS) and (b) the completers subgroup (CS).	3
Figure 3S. EDSS category trends at months 24, 48, and 96 by treatment group in the combined FREEDOMS population (a) full analysis set (FAS) and (b) the completers subgroup (CS).	4

Figure 1S. Study designs for the TRANSFORMS and FREEDOMS/FREEDOMS II trials and their extensions.




^aFollowing a protocol amendment, all patients receiving fingolimod 1.25 mg/day were gradually switched to fingolimod 0.5 mg/day in the extension phase

IFN: interferon; IM: intramuscular; M: month

Figure 2S. EDSS category trends at months 12, 24, 48, and 96 by treatment group in TRANSFORMS


(a) the full analysis set (FAS) and (b) the completers subgroup (CS).



Comparisons were made using the Mantel–Haenszel χ^2 test for trend, with the minimal change and fluctuating categories combined.

CS: completer subgroup; EDSS: Expanded Disability Status Scale; FAS: full analysis set; IFN-β-1a: interferon-beta-1a.

Figure 3S. EDSS category trends at months 24, 48, and 96 by treatment group in the combined FREEDOMS population (a) full analysis set (FAS) and (b) the completers subgroup (CS).



Comparisons were made using the Mantel-Haenszel χ^2 test for trend, with the minimal change and fluctuating categories combined.

CS: completer subgroup; EDSS: Expanded Disability Status Scale; FAS: full analysis set.